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ABSTRACT
Receptor-interacting protein kinase 2 (RIP2 or RICK, herein
referred to as RIPK2) is linked to the pathogen pathway that
activates nuclear factor k-light-chain-enhancer of activated
B cells (NFkB) and autophagic activation. Using molecular
modeling (docking) and chemoinformatics analyses, we used
the RIPK2/ponatinib crystal structure and searched in chemical
databases for small molecules exerting binding interactions
similar to those exerted by ponatinib. The identified RIPK2
inhibitors potently inhibited the proliferation of cancer cells
by . 70% and also inhibited NFkB activity. More importantly,
in vivo inhibition of intestinal and lung inflammation rodent
models suggests effectiveness to resolve inflammation with
low toxicity to the animals. Thus, our identified RIPK2 inhibitor
may offer possible therapeutic control of inflammation in
diseases such as inflammatory bowel disease, asthma, cystic
fibrosis, primary sclerosing cholangitis, and pancreatitis.
Introduction
Activation of nuclear factor k-light-chain-enhancer of acti-
vated B cells (NFkB) proceeds through multiple pathways
involving tumor necrosis factor receptor 1 (TNF-R1) and
pathogen-recognition receptors, such as Toll-like receptors
(TLRs) (Orlowski and Baldwin, 2002; Madrid and Baldwin,
2003; Hayden and Ghosh, 2004) and nucleotide-binding
oligomerization domain-containing protein 2 (NOD2), an
intracellular pattern-recognition receptor. NOD2 is mainly
stimulated by muramyl dipeptide (MDP), a bacterial prod-
uct found in both Gram-positive and Gram-negative bacte-
ria, and requires the obligate kinase, receptor-interacting
protein kinase 2 (RIPK2), to promote both NFkB activation
and an autophagic response (Tigno-Aranjuez et al., 2010).
Mice with genetic deletion of Nod2/Ripk2 have a dysbiotic
intestinal flora, resulting in altered susceptibility to intestinal
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N-(2-(4-amino-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methylpropyl)isonicotinamide.
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inflammation (Ermann et al., 2014). In addition, the loss of
Ripk2 has been demonstrated to result in the inability of cells
to carry out mitophagy, leading to enhanced mitochondrial
production of superoxide/reactive oxygen species and accumu-
lation of damaged mitochondria that will trigger a caspase
1–dependent inflammasome activation (Lupfer et al., 2014).
In the context of malignant transformation, knockdown of
RIPK2 downregulated mRNA expression of E-cadherin and
vimentin, both of which are involved in epithelial to mesen-
chymal transition and metastatic promotion (Wu et al., 2012).
RIPK2 might thus play an important role in cell migration
(Wu et al., 2012), metastasis (Wu et al., 2012), and offer
alternate novel therapeutics for abnormal inflammation
driven by the NOD2/RIPK2 pathway.
Most RIPK2 inhibitors were not designed to inhibit RIPK2,
and thus, RIPK2 inhibition was an off-target effect of the use
of these drugs. These included gefitinib/Iressa (IC50 at 50 nM)
(Canning et al., 2015), regorafenib, and other protein tyrosine
kinases (Canning et al., 2015). Tigno-Aranjuez et al. (2014)
reported on the identification of a novel class of RIPK2
inhibitors (OD36 [6-Chloro-10,11,14,17-tetrahydro-13H-1,16-
etheno-4,8-metheno-1H-pyrazolo[3,4-g][1,14,4,6]dioxadiaza-
cyclohexadecine] and OD38 [4,5,8,9-Tetrahydro-7H-2,17-
etheno-10,14-metheno-1H-imidazo[1,5-g][1,4,6,7,12,14]oxa-
pentaazacyclohexadecine]) that can inhibit 92% kinase
activity of RIPK2 at 100 nM and can alleviate inflammation
in a rodent model for inflammatory bowel disease. However,
like most RIPK2 inhibitors, at 100 nM, .80% inhibition of
10-FYN proto-ocogene, transforming growth factor 2 beta,
activin receptor like kinase 2, and lymphocyte specific
protein tyrosine kinase and Lck was also observed. WEHI-
435, a recently characterized small-molecule RIPK2 inhib-
itor, was demonstrated to delay RIPK2 ubiquitination
and NFkB activation downstream of NOD2 activation. In
addition, WEHI-435 (N-(2-(4-amino-3-(p-tolyl)-1H-pyrazolo
[3,4-d]pyrimidin-1-yl)-2-methylpropyl)isonicotinamide) inter-
fered with cytokine production in vitro and in vivo and
ameliorated experimental autoimmune encephalomyelitis in
mice (Nachbur et al., 2015). Recently, GlaxoSmithKline
isolated an RIPK2 inhibitor, GSK-583 (6-(tert-butylsulfonyl)-
N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine), based on using
the full RIPK2 protein to screen a DNA-encoded library
collection with a fluorescence polarization–based binding
assay as a readout (Haile et al., 2016). This bound to the
ATP binding pocket of the kinase domain and inhibited RIPK2
with an IC50 of 5–50 nM, depending on the assay. Last,
Novartis recently reported on their RIPK2 inhibitor, obtained
by virtual screening of their proprietary library, that can
inhibit RIPK2with an IC50 of 3 nM (He et al., 2017). No in vivo
applicability was analyzed, but it can selectively inhibit MDP-
promoted cytokine production in peripheral blood mononu-
clear cells and bone marrow–derived mouse macrophages. A
kinome analysis was not carried out, and thus, it is unknown if
significant off-target effects exist in the presence of the
Novartis RIPK2 inhibitor.
Because of robust off-target effects of most RIPK2 inhibi-
tors, we carried out molecular modeling (docking) and chem-
informatics analyses by carefully analyzing the only known
crystal structure of RIPK2 in association with the c-ABL
kinase inhibitor ponatinib (https://www.rcsb.org/pdb/explore/
macroMoleculeData.do?structureId=4C8B). Utilizing this
structure, we searched chemical databases for scaffolds
exerting significant binding interactions similar to (or stron-
ger than) those exerted by ponatinib, determined by compar-
ing their free energies when docked inside of the RIPK2
binding site. In addition to RIPK2 binding as part of this
computer-based (initial) screening, we selected compounds
that inhibited epidermal growth factor receptor (IC50
values .1000 nM; weak inhibitory activity) along with weak
binding interactions in the EGFR and c-ABL binding sites,
two common off-targets for previously identified RIPK2
inhibitors. Several hits are shown in Fig. 1 and Table 1, and
these compounds have unknown biologic features. Since
RIPK2 signals downstream of NOD2 and is linked to NFkB
and autophagy activation, we speculated that the in vivo use of
our selective RIPK2 inhibitors would target NFkB activation
and possibly resolve abnormal inflammation states.
Methods
Additional methods can be found in the Supplemental Experimen-
tal Procedures online.
Pharmacophore Search. Commercially available subsets of the
ZINC (15,868,179 compounds) and MolPort (7,241,662 compounds)
databases were screened using the lead drug ponatinib as a reference.
We used the ZINCPharmer pharmacophore search server (Koes and
Camacho, 2012), and pharmacophore features were identified directly
from the RIPK2 structure [Protein Data Bank (PDB) identifier: 4C8B]
and used for the screening. In this regard, a total of 74 compounds
were selected from both databases. The selected compoundswere then
docked into the RIPK2 binding site.
Structure Similarity Search. The PubChem (Kim et al., 2016)
compound library (more than 80 million molecules) was compared
with ponatinib to filter all molecules which are at least 60% similar to
this compound (10,655,787 molecules). We selected the most similar
($90%; 803 compounds) and less similar (,62%; 50,000 compounds
randomly selected from a total of 2,607,266) structures using the
PubChem Fingerprint implemented in the ChemmineR package
(Bioconductor, Seattle, WA) (Cao et al., 2008) of the R program (R
Development Group, Vienna, Austria). The filtered compounds were
then subjected to another filtering step based on Lipinski’s rule of five
(Lipinski et al., 2001), removing the duplicates and inorganic mole-
cules with the FAFDrugs3 server (Lagorce et al., 2015) (22,274
compounds). Finally, a total of 3000 compounds were selected and
optimized using the obminimize tool of the OpenBabel toolbox (Open
Babel, Pittsburgh, PA) (O’Boyle et al., 2011) for the docking studies.
Molecular Docking. The crystal structure of the human RIPK2
(PDB: 4C8B) (https://www.rcsb.org/pdb/explore/macroMoleculeData.
do?structureId=4C8B) was retrieved from the PDB (Bernstein et al.,
1977). Some residues in the three-dimensional structures were
missing, and consequently, these side-chain atoms were added using
theWHAT IF web interface (Vriend, 1990). The protein was subjected
to an energy minimization using the AMBER99SB force field by 1000-
step steepest-descent minimization followed by 100-conjugate gradi-
ent minimization using University of California, San Francisco
CHIMERA version 1.9 software (University of California, San Fran-
cisco, CA) (Pettersen et al., 2004). Polar hydrogens, Gasteiger-Marsili
empirical atomic partial charges, and the AutoDock atom types were
computed using the MGLTools version 1.5.4 package (Molecular
Graphics Laboratory at The Scripps Research Institute, La Jolla,
CA) (Morris et al., 2009). The torsional root and branches of the
ligands were chosenwith the same program, allowing flexibility for all
rotational bonds (except for the amide bond). In addition, the software
was used to assign Gasteiger-Marsili atomic charges to all ligands
(Gasteiger et al., 1978). Docking calculations were performed using
the AutoDock Vina software (Molecular Graphics Lab at The Scripps
Research Institute) (Trott and Olson, 2010). A grid box of 28 Å3 and
centered at the binding site was used to calculate the atom types
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needed for the calculation. A total of nine runswere performedwith an
exhaustiveness of 50. The best binding mode of each molecule was
selected based on the lowest binding free energy score. The three-
dimensional figures were generated using PyMOL Molecular
Graphics System (DeLano Scientific LLC, Palo Alto, CA).
RIPK2 In Vitro Kinase Assay. For this protocol, samples
were lysed in 1 RIPK2 lysis buffer [50 mM Tris (pH 7.5), 0 mM
MgCl2, 1% Triton X-100, 1 mM dithiothreitol, 1 mM EDTA, 1 mM
EGTA, with freshly added 1 mM b-glycerophosphate and protease
inhibitors (phenylmethylsulfonyl fluoride and aprotinin)] and
immunoprecipitated overnight using 1.5 mg rabbit anti-RIPK2 anti-
body. The next day, protein G sepharose was used to immunoprecip-
itate the RIPK2 protein complex immunoprecipitation (IP) for 1.5
hours. Following this incubation, samples were washed once in 1
kinase wash buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton
X-100, 1 mM EDTA] followed by two washes with 1 kinase buffer
[30 mM Hepes (pH 7.5), 10 mM MgCl2, 2 mM MnCl2]. After the last
wash, 20 ml of water was added to beads, followed by 1 kinase buffer
and 32P-g-ATP, and kinase reaction was allowed to proceed for
45–60 minutes at 30°C. Protein loading dye was added to the mix,
Fig. 1. (A) Schematic of the RIPK2 active site. (B) Representation of pharmacophore points: hydrogen bond donor (HBD, yellow), hydrogen bond
acceptor (HBA, orange), hydrophobic (Hyd, cyan) and aromatic (Ar, green). Predicted binding modes of ponatinib (green) (i), MolPort-016-359-762
(orange) (ii), and MolPort-016-412-727 (blue) (iii) in the RIPK2 binding site. (iv) Comparison between the binding position of ponatinib found within the
crystal structure (yellow) and the binding mode predicted by AutoDock Vina (green). Predicted binding modes of PC_57410628 (purple), PC_68349611
(brown) (v), and PC_44716361 (MolPort-001-746-327, orange) (vi) in the RIPK2 binding site. All hydrogens were omitted for clarity. The dotted lines
represent distances for the formation of hydrogen bonds.
356 Salla et al.
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and samples were boiled and separated on an SDS-PAGE gel. The gel
was dried and then exposed to X-ray film to capture the autophos-
phorylation of RIPK2.
NFkB Gene Reporter Luciferase Assay. The Dual-Luciferase
Reporter Assay System (E1910; Promega, Madison, WI) was used to
perform dual-reporter assays on NFkB luciferase and Renilla lucifer-
ase (internal control). In brief, HCT116 colon cancer cells were equally
seeded at a density of 3  104 in six-well plates and allowed to attach
for 24 hours. Prior to transfection, cells were washed with serum-free
medium three times. Dual transfection was carried out using 12 ml of
polyethylenimine to 3 mg of NFkB luciferase construct and 60 ng of
Renilla luciferase construct. Twenty-four hours after transfection,
cells were treated with the different drugs for 24–36 hours. Cells were
then lysed using the passive lysis buffer provided by the kit for
30 minutes on ice. Lysate was spun down for 8 minutes at 10,000 rpm,
and 20 ml of cell lysate was transferred into a 96-well plate. Luciferase
assayswere analyzed based on the ratio of Firefly/Renilla to normalize
cell number and transfection efficiency.
Intestinal Inflammation Injury Model. Animals were admin-
istered 3% (w/v) dextran sulfate sodium (DSS; molecular weight of
40,000–50,000;MPBiomedicals, SantaAna, CA) in the drinkingwater
for 7 days followed by recovery for 7 days. They were monitored for
piloerection, bloatedness, tremors, lack of movement, rectal bleeding,
andweight loss [all on a scale of 0–5, with 5 being very severe; adapted
from Madsen et al. (2001)]. Animals were euthanized once rectal
bleeding became grossly apparent. For weight loss, the following
scores were assigned: 0 for no weight loss, 1 if 5% loss, 2 for 5%–10%
loss, 3 for 10%–15% loss, 4 for 15%–20% loss, and 5 for .20% loss in
initial body weight. Disease activity indices were the sum of all
individual scores. All animals were male of the C57BL/6 background
and at 10–12weeks of age or 25 g in bodyweight at the beginning of the
experiment.
Lung Inflammation Model. Male Balb/c mice (6–8 weeks) were
sensitized on days 1 and 6 via intraperitoneal injection of 0.9% sterile
saline (0.5 ml) or 0.9% saline containing 10 mg of ovalbumin and 2 mg
of Al(OH)3. After light anesthesia with ketamine (75 mg/kg) and
acepromazine (2.5 mg/kg), mice were challenged intranasally with
25 ml of saline containing 50 mg of ovalbumin or saline alone as a
control on days 12 and 14. RIPK2 inhibitor 1 (1 mg/g body weight) or
30% dimethylsulfoxide (DMSO; solvent control for drug) was injected
intraperitoneally on days 12, 13, and 14 (on days 12 and 14, the
injection was performed 1 hour before the intranasal challenge with
ovalbumin). On day 15, mice were euthanized with an intraperitoneal
injection of 2 mg of sodium pentobarbital. Cardiac puncture was used
to collect blood, followed by tracheal intubation with polyethylene
tubing. The lungs were washed twice, with 1 ml of phosphate-buffered
saline, pH 7.4, and 2 ml of bronchoalveolar lavage (BAL) fluid
was collected. BAL fluid was spun at 300g for 5 minutes. Cell pellets
were resuspended in phosphate-buffered saline, total cell count was
performed, and then cytospins were prepared with 5000 cells. The
slides were stained with Diff-Quick (Polysciences, Warrington, PA),
and differential cell counts were performed to assess allergic airway
inflammation. This was done in collaboration with Dr. Harissios
Vliagoftis (University of Alberta, Edmonton, AB, Canada).
Mass Spectrometry. Direct-infusion measurements were carried
out on an LTQ Orbitrap XL mass spectrometer (Thermo Fisher
Scientific, Waltham, MA) using the Ion Max ESI source (Thermo
Fisher Scientific). The on-board syringe pump was used with a 100-ml
Hamilton syringe and a flow rate of 5 ml/min. The following
parameters were used: sheath gas flow of 15 arbitrary units, auxiliary
gas flow of 5 arbitrary units, spray voltage of 3.5 kV, tube lens voltage
of 110 V, capillary temperature of 275°C, capillary voltage of 35 V, and
capillary temperature of 275°C. The automatic gain control target was
set to 1e6 and the maximum injection time to 200 ms. The resolution
was set at 100,000, and two microscans were recorded.
NMR Spectroscopy. NMR experiments were run on a Varian
Inova 500 MHz spectrometer (Agilent, Santa Clara, CA) at 30°C. The
proton chemical shifts were measured relative to the residual pro-
tonated methyl (CHD2) signal of d6-DMSO (2.50 ppm); coupling
constants (J) are reported in Hz. Standard notation is used to describe
the multiplicity of signals observed in 1H NMR spectra: singlet (s),
doublet (d), triplet (t), broad (b), etc. Through-space and through-bond
connectivities were observed using a two-dimensional 1H-1H rotating-
frame Overhauser enhancement spectroscopy (1H-1H ROESY) exper-
iment (mixing time 200 ms). One-dimensional experiments were
processed using VNMRJ (Varian Associates, Palo Alto, CA), and
two-dimensional 1H-1H ROESY was processed using NMRPipe/NMR-
Draw software (Ad Bax group, Bethesda, MD). RIPK2 inhibitor 1 was
prepared by dissolving 0.3 mg in 500 ml d6-DMSO. RIPK2 inhibitor
2 was prepared by dissolving 0.3 mg in 500 ml of d6-DMSO (Delaglio
et al., 1995).
Use of Animals. All animal experimentation was performed in
accordance with the University of Alberta institutional guidelines as
defined by the Animal Care and Use Committee.
Statistical Analysis. Statistical analysis was carried out by
analysis of variance and Student’s t test (two-tailed) as indicated.
Results
Pharmacophore Search. The ponatinib/RIPK2 complex
(PDB: 4C8B) has revealed significant binding interactions of
this inhibitor in the RIPK2 active site. Based on this crystal
structure, the active site is localized in a binding pocket
formed by at least eight different amino acid residues, in-
cluding Val32, Lys47, Glu66, Ile69, Leu70, Thr95, Met98, and
Asp164 (Fig. 1A). In this work, the ZINC and MolPort
databases were screened with the ZINCPharmer pharmaco-
phore search server using the lead drug Ponatinib as a query.
Several pharmacophoric features were identified directly from
theRIPK2 structure and used for the screening. In this regard,
a total of 74 compounds were identified from both databases
with pharmacophoric points similar to ponatinib (Fig. 1B).
The compounds were then docked into the same RIPK2
binding site in which ponatinib is located. Interestingly,
54 compounds shared the pharmacophore distribution of
ponatinib. Table 1 summarizes the docking scores of the
compounds with the lowest binding free energies. Figure 1B
shows the location of the pharmacophoric points identified for
the interaction of ponatinib with the RIPK2 active site and the
proposed bindingmodes of the ligands with the lowest binding
free energies, respectively. It is noteworthy that the com-
pounds with the lowest calculated binding free energies
exhibit a high structural similarity between them [MolPort-
016-359-762 (labeled as RIPK2 inhibitor 1 in subsequent
TABLE 1
Calculated binding free energies of potential RIPK2 inhibitors
ZINC, MolPort, and PubChem (PC) molecule identification numbers are shown.
MolPort-016-359-762 is RIPK2 inhibitor 1 and PC_44716361 (MolPort-001-746-327)
is RIPK2 inhibitor 2.
Compound
DGbind
Compound
DGbind
kcal/mol kcal/mol
Pharmacophore
Ponatinib 211.9 MolPort-015-604-588 210.6
MolPort-016-359-762 211.5 MolPort-016-412-727 210.6
MolPort-015-752-252 210.8 ZINC02739307 210.1
Structure similarity
PC_57410628 212.0 PC_58945682 211.5
PC_44716361 211 8 PC_58945685 211.5
PC_24826801 211 8 PC_68349611 211.5
PC_57405602 211.6 PC_58945669 211.3
PC_58945635 211.6 PC_40780119 211.1
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figures, 3-benzamido-4-methyl-N-[3-(1-methyl-1H-imidazol-
2yl)phenyl]benzamide), MolPort-015-752-252, MolPort-015-
604-588, and MolPort-016-412-727) and a high correlation
with pharmacophoric points of ponatinib. These results
suggest that compound MolPort-016-359-762 and its deriva-
tives have a high probability of inhibiting RIPK2.
Structure Similarity Search. A total of 10,655,787 com-
pounds with at least 60% similarity to ponatinib were
obtained from the PubChem database to dock them into this
binding site and identify new potential inhibitors. We selected
the most similar ($90%; 803 compounds) and less similar
(,62%; 50,000 compounds randomly selected from a total of
2,607,266) structures to identify ponatinib-like molecules and
novel scaffolds, respectively. After filtering with Lipinski’s
rule and removing duplicates and inorganic molecules, we
performed molecular docking studies in the RIPK2 active site
using AutoDock Vina, from which more than 500 compounds
with a calculated DGbind #210.0 kcal/mol were identified.
The docking scores of ponatinib and the compounds with the
lowest binding free energies are summarized in Table 1. As
might be expected, the compounds with the highest simi-
larity in values showed similar binding modes compared
with ponatinib (PC_24826801, PC_57405602, PC_58945635,
PC_58945682, and PC_58945685). However, compound
PC_57410628 was the only molecule with a lower binding
free energy than the lead molecule. Moreover, compound
PC_44716361 [MolPort-001-746-327 (labeled as RIPK2 in-
hibitor 2 in subsequent figures)], which presents a lower
similarity to ponatinib, represents a new scaffold with unique
structural features offering alternatives from a medicinal
chemistry perspective. Figure 1B shows the proposed binding
mode of these ligands in the RIPK2 binding site. This figure
also shows that all of the compounds identified possible form
hydrogen bonds between the Glu66 residue and the carbox-
amide group. The initial virtual screening, ranking chemical
structures, and the pan-assay interference compounds check
of the selected compounds (Sterling and Irwin, 2015) are
reported in Supplemental Table 1.
Utilizing mass spectrometry and 1H-NMR (Fig. 2; Supple-
mental Figs. 1–3A), we confirmed.95% purity of our two lead
compounds and confirmed the structure of the identified
RIPK2 inhibitors 1 and 2. ROESY spectra provided through-
bond and through-space connectivities that were essential for
obtaining complete chemical shift assignments of both mole-
cules (Supplemental Figs. 1 and 2). In addition, through-space
rotating-frame nuclear Overhauser enhancement (ROE) con-
nectivities provided valuable information about the confor-
mational preferences of RIPK2 inhibitor 1 in solution
(Fig. 2B). The lack of ROEs between HN22 and either HC17
or HC25 indicates that the central methyl-containing aro-
matic ring is roughly perpendicular to the amide plane of
HN22, as would be expected based on steric considerations.
In contrast, HN13 shows ROEs to HC8, HC17, and HC21,
indicating that the two central benzene rings are more planar
with respect to the central amide bond of HN13, similar to
the conformation seen in ponatinib (Fig. 1B). Thus, the
arrangement of benzene rings found in RIPK2 inhibitor
1 resembles the geometry of the corresponding aromatic rings
in ponatinib bound to RIPK2. The presence of both
HN13–HC17 and HN13–HC21 ROEs suggests rotation about
the C14–C16 bond, with rotomer i (Supplemental Fig. 1B)
matching the conformation found in ponatinib-RIPK2.
However, the presence of an HN13–HC8 ROE coupled with
the absence of an HN13–CH10 ROE suggests that rotation
about the C9–N13 bond is more restricted, which may force
the imidazole ring of RIPK2 inhibitor 1 into a position
opposite to the corresponding CF3 group of ponatinib-
RIPK2 (Fig. 1B, panel iii), which would place it in a more
solvent-exposed position than the buried position of the CF3
group. Further detailed analysis may be warranted to isolate
these two forms and determine bioactivities for RIPK2 and
NFkB inhibition.
Validation of RIPK2 Inhibitors Using Kinome Anal-
ysis. The specificity of the identified RIPK2 inhibitors to
inhibit numerous kinases was explored utilizing the Kinome
Scan profiling service at DiscoverX (Fremont, CA). This
utilizes an in vitro kinase approach with purified recombi-
nant kinases/peptide substrates to determine activity of
kinases in the panel. We explored if our lead compounds,
RIPK2 inhibitors 1 and 2, can inhibit other targets at 100 nM
in the 97 kinome panel (Supplemental Table 2A). This
concentration was used due to robust inhibition of NFkB
and RIPK2 kinase assay in assays outlined in Figs. 2–6. The
kinome inhibition analysis revealed robust selectivity to-
ward RIPK2 for RIPK2 inhibitor 1 with 20%–27% inhibition
of c-ABL, Aurora kinase B, or ERBB2 (Supplemental
Table 2A). RIPK2 inhibitor 2 appears to inhibit 38% of the
activity of SNARK and 27% of the activity of FGFR2, GSK3-
b, JNK1, CSNK1G2 (casein kinase 1), and MET tyrosine
kinase. These off-target inhibitions are not surprising, as it is
difficult to obtain a specific small-molecule inhibitor. This
would suggest possible activities beyond inhibiting RIPK2
that will need to be empirically tested. Initial empirical
testing for c-ABL was carried out via an in vitro kinase
approach with purified recombinant kinases at the MRC
Protein Phosphorylation andUbiquitinationUnit in Dundee,
Scotland. Both of our RIPK2 small-molecule lead compounds
inhibited c-ABL but with an IC50 of.100 mM (Fig. 3A). Given
this observation, we hope that the off-target effects on Aurora
kinase B and ERBB2 (if any) will also be in a vastly different
concentration range of 100 nM.
Cell-Based Confirmation of RIPK2 Inhibition and
Inhibition of NFkB Activation. We next explored cell-
based in vitro inhibition of RIPK2. We can clearly observe
RIPK2 inhibitor 1 and 2 inhibition of MDP-dependent activa-
tion of RIPK2 autophosphorylation (on tyrosine 474) using an
in vitro kinase assay in HCT116 cells (Fig. 3B). MDP is the
molecular ligand for the NOD2 pathogen receptor whereby
RIPK2 can be activated. Similar results for RIPK2 inhibitor
1 inhibition of RIPK2 were obtained in breast cancer cells
(BT549 and MDA-MB231 cells, data not shown). Immunode-
pletion using an anti-RIPK2 antibody (Fig. 3C, condition B) or
Crispr/Cas9 knockout of RIPK2 (Fig. 3D) confirmed specificity
of detection of the autophosphorylated RIPK2 band in Fig. 3B.
Furthermore, using a phospho-tyrosine [Y] 474 (in-house
generated) and a phospho-serine [S] 176 (Cell Signaling,
Inc., Danvers, MA) RIPK2 antibodies, we confirmed that
active RIPK2 is recognized by these antibodies upon activa-
tion with MDP treatment in 293HEK fibroblast and HCT116
colon cancer epithelial cells (Fig. 3E, left panel) and detection
of constitutively active RIPK2 in the colon cancer cell line
SW480 (Fig. 3E, right panel). Interestingly, we can observe
constitutively active RIPK2 in Hodgkin’s lymphoma cell lines
HDMYZ, L428 (Fig. 4A), and KMH2 cells (Fig. 4B). This signal
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Fig. 2. Mass spectrometry and NMR confirmation of mass and structure of RIPK2 Inhibitor 1. (A) Direct-infusion measurements were carried out on an
LTQ Orbitrap XL (Thermo Scientific) mass spectrometer using the Ion Max ESI source. Mass confirmation was obtained as indicated. (B) Two-
dimensional 1H-1H ROESY spectrum of 3-benzamido-4-methyl-N-[3-(1-methyl-1H-imidazol-2-yl)phenyl]benzamide. Boxes (orange) represent through-
space connectivities between protons in the compound. Blue boxes are signals due to three-bond J-coupling between aromatic ring protons. Four-bond
J-coupling signal is less intense. AV, number of scans that were averaged; FTMS, Fourier Transform Mass Spectrometry; NL, normalized level; RT,
retention time.
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Fig. 3. Analysis of RIPK2 kinase activity. (A) Kinase activity for c-ABLwas tested in the presence of inhibitors 1 and 2. IC50 for c-ABL for both inhibitors
is .100 mM. Analysis was carried out using purified c-ABL and the substrate peptide, EAIYAAPFAKKK, in association with the MRC Unit on
Phosphorylation and Ubiquitination, University of Dundee, Scotland. (B) RIPK2 autophosphorylation (Auto-P) at site Y474 is shown. Inhibition was
carried out on cells followed by lysis and IP with rabbit anti-RIPK2 overnight. Following protein G pull down and wash, 32P-g-ATP was added and kinase
reaction was allowed to proceed for 30 minutes at 30°C. Following kinase reaction, SDS-PAGE was used to separate out the proteins, and gel was then
dried and exposed to film. (C) RIPK2 in HCT116 cells were IP with an anti-RIPK2 antibody (A) and the supernatant after IP in (A) was IP in (B) with the
same RIPK2 antibody, and in vitro kinase (IVK) assay was carried out on both samples. (D) Crispr/Cas9 knockout of RIPK2 in HCT116 colon cells was
carried out, followed by MDP activation and RIPK2 IVK analysis to illustrate use of RIPK2 Crispr/Cas9 reagents and specificity of our IVK assay. (E)
Left panel: cells were stimulated with MDP for 3 hours, and RIPK2 activation was monitored by a phosphotyrosine (pY) 474 RIPK2 antibody (in-house
antibody) and phosphoserine (pS)176 phosphorylation (Cell Signaling). Right panel: several colon cancer cells were investigated for constitutive
activation of RIPK2 using phosphorylation specific antibodies to pY474 and pS176 as indicated. Bottom: constitutive activation of RIPK2 in numerous
cell lines are explored. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IB, immunoblotting.
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can effectively be inhibited using RIPK2 inhibitors 1 and 2 and
regorafenib (a known RIPK2 kinase inhibitor) at 100 nM as
determined using RIPK2 phospho-specific antibodies (Fig. 4,
A and B). Furthermore, we determined that RIPK2 inhibitor
1 effectively inhibited KHM2 cells at an approximate IC50 of
5–10 nM, and kinase activity was somewhat sensitive to
detergent conditions (Fig. 4, B and C). When compared with
inhibition with ponatinib (a known RIPK2 inhibitor and
chemical template for selecting our RIPK2 small molecule),
our RIPK2 inhibitor performed equally to inhibit RIPK2
kinase activity in an in vitro kinase assay in two different cell
lines (Fig. 4D).
The functional consequence of inhibiting MDP-dependent
activation of RIPK2 is the loss of NFkB activity (Fig. 5;
Supplemental Fig. 3B) and DNA binding ability, especially
for the interleukin-8 (IL-8) promoter (Supplemental Fig. 4A).
Not surprisingly, RIPK2 inhibitor 1 was more efficacious at
100 nM at inhibiting NFkB activity when compared with
RIPK2 inhibitor 2, gefitinib, or regorafenib (P values com-
paring RIPK2 inhibitor 1 vs. RIPK2 inhibitor 2, gefitinib, and
regorafenib inhibition of MDP-driven NFkB activation were
0.0015, 0.0006, and 0.004, respectively). However, RIPK2
inhibitor 1 was as efficacious as ponatinib at 100 nM for
NFkB inhibition (P value 5 0.06 when comparing RIPK2
inhibitor 1 vs. ponatinib inhibition of MDP-driven NFkB
activation). Interestingly, a recently characterized RIPK2
inhibitor, GSK-583 (Haile et al., 2016), did not inhibit MDP-
dependent NFkB activity at 100 nM in HCT116 cells (data
not shown), although it is known to in primary immune
cells. Interestingly, we did observe a small but significant
Fig. 4. Characterization of RIPK2 kinase inhibitors. (A) Immunoblot illustration of the use of RIPK2 phospho-antibodies in two Hodgkin’s lymphoma
cells that have constitutive active RIPK2. A comparison with a known RIPK2 inhibitor is shown (regorafenib). All inhibitor concentrations were 100 nM.
Similar results were observed for a third Hodgkin’s lymphoma cell line, KMH2 [see (B)]. (B) KMH2 Hodgkin’s lymphoma cells were inhibited in vivo for
33–36 hours using the indicated concentration of RIPK2 inhibitor 1. (Top) An in vitro kinase assay was carried out by IP overnight with 1 mg of the rabbit
anti-RIPK2 antibody from ProteinTech (Rosemont, IL) and 1 ml of lysate from a confluent six-well dish of KMH2 cells. Immune complexes were
separated by SDS-PAGE and captured by autoradiography. (Bottom) Quantitation of three to five independent experiments to reveal an approximate
IC50 of 5–10 nM for in vivo RIPK2 inhibition. (C) Analysis of effect of drug solvent (DMSO), salt concentration, and detergents on the kinase activity of
RIPK2. Following IP, the indicated reagents were added for 10minutes followed by 32-g-ATP to initiate the kinase reaction as described in theMaterials
and Methods section. (D) RIPK2 in vitro kinase assay was carried out as in Fig. 3B in KMH2 and HCT116 cells in the presence of ponatinib or RIPK2
inhibitor 1 to carry out a comparison of RIPK2 inhibition. IB, immunoblotting.
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reduction in lipopolysaccharide (LPS; via TLR4 and TLR2),
TNFa, and IL-1b–dependent activation of NFkB (Fig. 5C and
an approximate IC50 in Fig. 5C, right panel; Supplemental
Fig. 3B). Although a reduction, the approximate IC50 for
RIPK2 inhibition of LPS-driven NFkB activation is .20 mM,
and we speculate it will also be much higher for inhibition of
TNFa and IL-1b–dependent activation of NFkB. Interest-
ingly, RIPK2 inhibitor 1 can also inhibit the activation of
hypoxia-response element I response to chemical induction
using 1% H2O2 (Supplemental Fig. 3C) to suggest either a
link to inflammation or a direct modulation of hypoxia-
inducible factor a function. These observations validate the
specificity of our RIPK2 inhibitor for NOD/RIPK2 biology
and usefulness as an in vivo inhibitor of MDP-driven
inflammation.
RIPK2 Inhibitors Can Inhibit the Proliferation of
Several Cancer Cells but Do Not Promote Apoptosis or
Cell Cycle Arrest. Inflammation is a strong driver of
malignant transformation and abnormal proliferation, espe-
cially in the colon (Lasry et al., 2016) and breast (Suman et al.,
2016). We explored the ability of RIPK2 inhibitors to reduce
the proliferative rate of highly metastatic cancer cells. For
most of the cancer cells, 45–100 nM RIPK2 inhibitor
1 inhibited.70% of the proliferation of colon and blood cancer
cells while preserving the proliferation of normal Rat-1 and
ModeK intestinal epithelial cells (Fig. 6A). These data would
suggest strong suppressive properties of RIPK2 inhibitor
1 and, to some extent, inhibitor 2 on cell proliferation.
Regorafenib, a recently characterized RIPK2 inhibitor, did
not significantly inhibit the proliferation of these cells in an
Fig. 5. RIPK2 Inhibition of NFkB activ-
ity. (A and B) NFkB gene reporter assay
determination of inhibition of MDP-
stimulated NFkB activity with RIPK2
inhibitors (A) and an approximate IC50
determination for inhibition of MDP
driven-NFkB activation using RIPK2
inhibitors 1 and 2 (B). All drugs in (A)
were used at 100 nM. P values for RIPK
inhibitor treated vs. MDP (no drug)
were ,0.0001 (inhibitor 1), 0.06 (in-
hibitor 2), ,0.006 (gefitinib), 0.0002
(regorafenib), and 0.0008 (ponatinib).
For ponatinib, n = 4 and n = 10 for the
rest with approximate IC50 curves
shown in (B). (C) Left panel: NFkB gene
reporter assay determination of inhibi-
tion of LPS-stimulated NFkB activity
with RIPK2 inhibitors (concentration
as indicated). P values for RIPK2 in-
hibitor treated vs. LPS (no drug)
were ,0.02 (inhibitor 1) and ,0.268 (for
inhibitor 2) (n = 6). Right panel: approx-
imate IC50 determination for inhibi-
tion of LPS-NFkB–driven inflammation
using RIPK2 inhibitors 1 and 2 (B).
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Fig. 6. In vivo inhibition of proliferation, intestinal, and lung inflammation using RIPK2 inhibitors. (A) RIPK2 inhibitors modulate the proliferation of
several colon cancers but not normal cells. MTT assay was carried out with the indicated concentrations of RIPK2 inhibitors in the indicated cell lines.
HCT116 and DLD-1 are colon cancer cell lines, whereas RAT-1 andMODEK are normal rat andmouse intestinal cell lines, respectively. RIPK2 inhibitor
1 does not appear to interfere with proliferation of normal intestinal cells (Rat-1 andModeK) at 45 nM. For all experiments, n = 5–29. P value of HCT116
(+ inhibitor 1) vs. HCT116 (+ inhibitor 2) was ,0.03; DLD-1 (+ inhibitor 1) vs. DLD-1 (+ inhibitor 2) was ,0.02; DLD-1 (+ inhibitor 1) vs. DLD-1
(+ regorafenib) was,0.006. For RIPK2 inhibitor 1–treated DLD-1 or HCT116 vs. RIPK2 inhibitor 1–treatedModeK or Rat-1 cells (normal cells), P, 0.002
(analysis in either cell type); for RIPK2 inhibitor 2–treated DLD-1 or HCT116 vs. RIPK2 inhibitor 2–treatedModeK cells (normal cells), P, 0.02 and 0.098
(analysis in DLD-1 or HCT116 cells, respectively); for regorafenib-treated DLD-1 vs. regorafenib-treated ModeK (normal cells), P , 0.2 but .0.05. (B)
Intestinal inflammation injury was carried out using the DSS model. DSS is taken up in the drinking water and migrates to the colon to cause irritation
and localized inflammation. Rassf1a2/2mice are extremely sensitive to this model, with ,25% survival following a 3% DSS insult for 7 days followed by
water for 7 days. Most Rassf1a2/2mice require euthanasia by days 7–9. Disease activity is scored based on rectal bleeding, piloerection, movement, and
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MTT assay (3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazo-
lium bromide) (Fig. 6A). We also observed inhibition of triple
negative breast cancer cells, HCT1143 andMDA-MB231, with
RIPK2 inhibitor 1 (Supplemental Fig. 4B), suggesting effec-
tive antiproliferative properties. The approximate IC50 for
inhibition was around 30–60 nM for most of the cells tested
(two are shown in Supplemental Fig. 4C). This effect on
growth inhibition was not due to alterations in cell cycle
(Supplemental Fig. 5) nor a significant increase in the
apoptotic cell populations, suggesting that RIPK2 inhibition
of proliferation is independent of cell cycle or apoptotic
changes.
RIPK2 Inhibitors Do Not Inhibit RIP1-Directed Cell
Death, Ferroptosis, or Modulation of Mitochondrial
Physiology. The RIPK family of proteins are actively in-
volved in numerous cell-death processes beyond death
receptor–dependent cell death (Vanden Berghe et al., 2016).
We characterized two forms of cell death involving erastin-
stimulated ferroptosis (an iron-dependent form of cell death,
Supplemental Fig. 6A) and VAD-fmk, Smac Mimetic-164, and
TNFa stimulation of RIPK1-directed cell death (Supplemen-
tal Fig. 6B). In both cases, RIPK2 inhibitor 1 did not interfere
with these forms of cell death to support our cell-cycle effects
and to suggest no overlap with RIPK1 biology (Supplemental
Fig. 6A). Recently, RIPK3 was demonstrated to require a
Bax/Bak effect on the mitochondrial permeability transition
pore to carry out necroptosis, and the importance of both
RIPK1 and RIPK3 in relation to necroptosis-directed de-
generative, inflammatory, and infectious diseases has been
published (Moriwaki et al., 2015). We thus explored how the
identified RIPK2 inhibitors can perturb mitochondrial phys-
iology by evaluating the activity of the sirtuins, a class of
deacetylases that use NAD1 to remove acetyl groups from
proteins (Tang, 2016). Indeed, the putative SIRT1 activator
resveratrol can stimulatemitochondrial biogenesis to promote
increasedwellness in the individual (Ostojic, 2017). Therefore,
we explored the effect on sirtuin activity using the BIOMOL
assay (Enzo Life Sciences, Farmingdale, NY) as described
previously (Dai et al., 2016). We observed no statistically
significant increase in SIRT1 activation when using the
compounds at 0.1 or 10 mM, indicating that phenotypes
observed for the use of RIPK2 inhibitors at these doses in
cells are likely through SIRT1-independent mechanisms
when compared with the effect of resveratrol (Supplemental
Fig. 6C). The identified RIPK2 inhibitors are thus selective
inhibitors of RIPK2-dependent NFkB pathways if we consider
the data in Fig. 5 and Supplemental Figs. 3B, 4, and 5.
RIPK2 Inhibitors Can Efficiently Resolve Intestinal
Inflammation in an Ulcerative Colitis Model. DSS-
induced intestinal inflammation is a model for ulcerative
colitis [a form of inflammatory bowel disease (IBD)]. DSS
functions to irritate the colonic mucosa to promote localized
inflammation, active cell death, and localized destruction of
the epithelial barrier to the lumen of the colon (Dieleman
et al., 1998). These events subsequently drive inflammation
damage indicative of what IBD patients encounter. NOD2
mutations have been observed in IBD patients, lending
support for dysregulated NOD2/RIPK2 signaling driving in-
flammation in IBD patients (Branquinho et al., 2016). We
have demonstrated the importance of Ras association domain
family protein 1A [RASSF1A (or 1A)] in the pathogenesis of
colitis in a rodent model (Gordon et al., 2013). RASSF1A is a
tumor suppressor involved in TNF-R1–dependent apoptosis,
cell cycle control, and restriction of NFkB activation (Gordon
et al., 2013). The Rassf1a knockout mice (both heterozygous
and homozygous forms) are very susceptible to DSS-induced
inflammation injury (Gordon et al., 2013) mainly due to
uncontrolled inflammation linked to the NOD2/RIPK2 path-
way (Said et al., unpublished observation).
Therefore, we carried out intraperitoneal injection of 1 mg/g
body weight of RIPK2 inhibitor 1 or 2 on days 5, 7, and 9 to
offset the preinflammation damage stage, peak inflammation
damage stage, and postinflammation damage/restitution
phase. Using this treatment scheme, we observed a robust
difference on day 9 in the disease activity indices of wild-type
and Rassf1a knockout mice that was significantly inhibited
with the use of the RIPK2 inhibitors, especially RIPK2
inhibitor 1 (Fig. 6B; Table 2). Interestingly, a newly charac-
terized RIPK2 inhibitor, gefitinib, can also inhibit intestinal
inflammation injury but only promote a 41% survival versus
73% survival with RIPK2 inhibitor 1 (Fig. 6B; Table 2).
Similar results were obtained for the protein tyrosine kinase
inhibitor regorafenib (data not shown). Since both gefitinib
and our RIPK2 inhibitors can inhibit RIPK2, either our drug
TABLE 2
Survival of Rassf1a2/2 animals during DSS-induced inflammation
The presence of RIPK2 inhibitors reduced acute intestinal inflammation and enhanced overall survival of the mice.
RIPK2 Inhibitor Treatment and Genotype Percentage Survival
No drug DSS-treated Rassf1a2/2 7/30 = 22%
1 (MolPort-016-359-762) DSS-treated Rassf1a2/2 8/11 = 73%
2 (MolPort-001-746-327) DSS-treated Rassf1a2/2 5/9 = 56%
Gefitinib DSS-treated Rassf1a2/2 7/15 = 47%
body weight changes as described previously (Madsen et al., 2001). N = 10–25 and P value of Rassf1a2/2 (DSS) vs. wild type (DSS) was ,0.0001;
Rassf1a2/2 (DSS) vs. 1a2/2 (DSS + inhibitor 1 or 2 or gefitinib) was,0.0001. (C) In vivo inhibition of lung inflammation in an ovalbumin-induced asthma
model in mice. Sensitization and challenge with ovalbumin (OVA) in this model induce accumulation of inflammatory cells in the BAL that are primarily
eosinophils. Administration of RIPK2 inhibitor-1 significantly decreased both the number of total cells and the number of eosinophils in the BAL fluid (n =
8 for each group). P values for comparison between OVA alone and OVA + RIPK2 inhibitor-1 were 0.019 for total cell numbers and 0.003 for eosinophils.
Please note that RIPK2 inhibitor 2 was not used in this experiment due to its higher approximate IC50 for NFkB (see Fig. 5B). (D) Model for disruption of
NOD2/RIPK2 biology in the presence of RIPK2 inhibitor 1. RIPK2 is activated via tyrosine (Y) (pY474) and serine (S) (pS176) phosphorylation and
ubiquitination events to allow for associations with downstream components. RIPK2 inhibitor 1 inhibits phosphorylation at serine 176 and tyrosine
474 and possible inhibition of ubiquitination of RIPK2.
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has more affinity for RIPK2 or the off-target effects of RIPK2
inhibitor 1 are beneficial to aid in recovery from inflammation
injury using the DSS model.
We then explored pharmacokinetic properties of RIPK2
inhibitor 1 in the sera of mice. Analysis revealed that RIPK2
Inhibitor 1 can be eluted at ∼3.7 minutes in a region of the
chromatogram free of interfering substances (Supplemental
Fig. 6D, top panel). After a dose of 1–2 mg/kg IP of inhibitor,
the compound was not quantifiable inmouse serum. However,
after dosingmice with 15mg/kg IP, the RIPK2 inhibitor was of
measurable concentrations in most of the serum samples
assayed. The mean Cmax was 114 ng/ml occurring at 1 hour
after dosing, and the area under the serum concentration
versus time curve was 573 ng  h/ml, with a terminal phase
half-life of 1.9 hours observed. Therefore, it appears that
RIPK2 inhibitor 1 may be efficiently metabolized within
2 hours and cleared from the blood (Supplemental Fig. 6D,
bottom panel). Furthermore, toxicity analysis carried out
9 days after the last dose of intraperitoneal injection of
2 mg/g body weight revealed little or no changes in .98% of
the markers characterized in a complete blood count (Supple-
mental Fig. 7). However, creatine kinase activity was signif-
icantly elevated in animals treated with RIPK2 inhibitor 1 as
opposed to RIPK2 inhibitor 2. During treatment with RIPK2
inhibitor 1 (and post-treatment), we did not overtly observe
phenotypic changes in these animals nor notice evidence of
health conditions to support a creatine kinase abnormality
(such as skeletal muscle defect and movement abnormalities
or unexpected euthanasia due to a cardiac abnormality).
Interestingly, it has been shown that the creatine/phosphoc-
reatine pathwaymay play a central role in energymetabolism,
and nutritional creatine supplementation has been shown to
impart beneficial effects in a number of diverse disease
pathologies (Kitzenberg et al., 2016). We speculate this to be
the case, as resetting of metabolic abnormalities is needed for
recovery of IBD patients who have metabolic syndrome
disorder (Goncalves et al., 2015). Further analysis is required
to determine if elevated creatine kinase affects the health of
the animal, how sustained it is, and if it can be alleviated with
RIPK2 inhibitor 1 analogs. In addition, detailed analysis is
needed on how our RIPK2 inhibitor 1 is metabolized and
removed from the blood, where it accumulates, or if it can cross
the blood-brain barrier. These are all unanswered questions
that we are currently addressing.
RIPK2 Inhibitors Can Also Efficiently Resolve Lung
Inflammation in an Asthma Model. RIPK2 has also been
implicated in allergic airway inflammation. RIPK2 gene
silencing in the airways decreased allergic airway inflamma-
tion in an ovalbumin-mediated mouse model of asthma (Jun
et al., 2013). Furthermore, an association between a RIPK2
promoter polymorphism and childhood severe asthma has
been shown in a Japanese population (Nakashima et al.,
2006). Since we observed robust inhibition of NFkB in the
presence of RIPK2 inhibitor 1 and a.70% recovery of animals
from DSS-induced inflammation injury (Figs. 4 and 6B), we
proceeded to explore the ability to resolve lung inflammation
using the ovalbumin challenge model (Kumar et al., 2008).
Ovalbumin elicits a robust inflammatory reaction in the
airways characterized by an increased number of total cells
and eosinophils in the BAL of ovalbumin-sensitized mice (Fig.
6B). In the presence of RIPK2 inhibitor 1 (and, to some extent,
with RIPK2 inhibitor 2), we observed a significant reduction in
both total cell numbers and eosinophil numbers in BAL fluid.
These data suggest effective inhibition of lung inflammation.
Discussion
RIPK2 is the obligate kinase to theNOD2 pathogen receptor
pathway and has been demonstrated to be involved in NFkB
activation and metastatic behavior in some cancers (Jun
et al., 2013) and has a distinct activity versus RIPK1, 3, or 4
(Chirieleison et al., 2016). In addition, several reports suggest
involvement in the activation of the immune response upon
viral infection (Lupfer et al., 2013) and the requirement for
the NOD2/RIPK2 molecular pathway in several models on
inflammatory diseases, including experimental colitis
(Branquinho et al., 2016) and arthritis (Vieira et al., 2012).
Colorectal cancer (CRC) is only one example of a disease that
can arise from a prior state of persistent or chronic inflamma-
tion. Individuals with IBD and primary sclerosing cholangitis
(inflammation of the bile ducts) are at a much higher risk for
progressing to CRC and require closer management of their
debilitating disease (Dyson and Rutter, 2012; Williamson and
Chapman, 2015). As such, therapies to modulate and control
inflammation are robust cancer-prevention strategies.
Herein, we performed pharmacophore and similarity-based
search and molecular docking studies toward the identifica-
tion of potential novel RIPK2 inhibitors. In the pharmaco-
phore search, we identified several molecules that share the
pharmacophore arrangement with ponatinib. From these,
compound MolPort-016-359-762 is one of the most attractive
molecules to be tested since it exhibits a high correlation with
the pharmacophore model and lowest binding free energy
(highest score). Moreover, the similarity-based virtual screen-
ing predicted 10 molecules as new potential RIPK2 inhibitors.
The lower docking score of one of the less-similar compounds,
MolPort-001-746-327, presents amore attractive scaffold to be
repositioned as an inhibitor of this enzyme. Interestingly,
several analogs of MolPort-016-359-762 also showed higher
affinities for the active site pocket of RIPK2, suggesting a high
preference of this scaffold for the active site pocket. These
analogs may even afford a greater selectivity to inhibit RIPK2
(data not shown). We are currently exploring the use of these
analogs of MolPort-016-359-762.
As mentioned earlier, several RIPK2 inhibitors have been
characterized. However, like most RIPK2 inhibitors, at
100 nM, OD36 and OD38 can also inhibit 10-FYN proto-
ocogene, transforming growth factor 2 beta, activin receptor
like kinase 2, and Lck by .80%. Our identified RIPK2
inhibitors reveal lower binding free energies that other RIPK2
inhibitors identified, suggesting that our inhibitor may be
more active. Furthermore, our identified RIPK2 inhibitors
appear to have more affinity for the active site of RIPK2 than
others, are more efficacious at inhibition of proliferation, and
can effectively resolve lung inflammation and intestinal in-
flammation more robustly than gefitinib (Fig. 6B; Table 2).
The efficacious quality of RIPK2 inhibitor 1 in resolving
intestinal inflammation may arise from the fact that it can
have a small but significant effect on TNFa-, IL-1b-, and LPS-
driven NFkB activation as seen in Fig. 5 and Supplemental
Fig. 3B. Most inflammatory diseases are complex diseases
that have amultitude of inflammatory pathways targeting the
area. Thus, to effectively resolve inflammation in these areas,
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a broad-spectrum inhibitor may be needed to target multiple
TLRs and pathogen receptors (Murgueitio et al., 2017).
All of our in vivo inhibition was at 1–2 mg/g body weight,
which is much lower than the level used for most small-
molecule inhibitors. Preliminary pharmacokinetics suggest a
1.89-hour half-life in the blood (Supplemental Fig. 6D), and
chronic experiments using RIPK2 inhibitor 1 agree with our
preliminary pharmacokinetics, suggesting the efficacious
quality of this inhibitor can last for up to 5–6 days after a
1–2-mg/g body weight intraperitoneal injection (data not
shown). We are currently completing our pharmacokinetic
analysis and will be exploring inhibition of intestinal in-
flammation in the IL-102/2 model for inflammatory bowel
disease, a model with spontaneous colonic inflammation by
8–10 weeks of age and an established model for IBD (Kuhn
et al., 1993).
It has been demonstrated by several groups that RIPK2 has
a unique requirement for NOD1 and NOD2 and functions in
many pathways different from RIPK1, 3, or 4. Recently,
Chirieleison et al. (2016) summarized the uniqueness of
RIPK2 kinase domain within the RIPK family that could not
be substituted for the kinase domain from RIPK1 or RIPK4.
Indeed, RIPK2 inhibitors 1 and 2 did not inhibit RIPK1
biology nor ferroptosis, a form of cell death influenced by
proteins of the RIPK family (Supplemental Fig. 6, A and B). As
such, we believe that our identified RIPK2 inhibitors 1 and
2 can selectively modulate RIPK2-specific biology in agree-
ment with the observations by Chirieleison et al. (2016).
Although we can observe a robust inhibition of autophos-
phorylation of RIPK2, NFkB, and alleviation of intestinal and
airway inflammation injury in our mouse models of colitis and
asthma, our kinome screen demonstrated in vitro inhibition of
several other kinases, including 20%–30% inhibition of c-ABL,
Aurora kinase B, or ERBB2. We have demonstrated the
importance of c-ABL in driving inflammation injury in our
acute DSS model in the publication by Gordon et al. (2013). It
is likely that our RIPK2 inhibitor 1 may interfere with the
kinase activity of these off targets indirectly by resolving the
inflammation. Many of these kinases are involved in growth-
related pathways, tumorigenesis pathways, and cell cycle
control, such as Aurora kinase B (Borisa and Bhatt, 2017).
These off-target effects may actually be beneficial in treating
IBD, primary sclerosing cholangitis, primary sclerosing
cholangitis/IBD-related CRC, and asthma, whereby a multi-
tude of abnormal signaling involving inflammation, oxidative
damage, DNA damage, and apoptotic abnormalities exists to
manifest itself into a diseased state. Thus, eliminating all of
these abnormalities using a single small molecule will pro-
mote a return to homeostasis and recovery from inflammation
damage. It will be interesting to explore other inflammation
states such as obesity, diabetes, cystic fibrosis, psoriasis, and
arthritis to determine the importance of RIPK2 in driving
inflammation damage and the usefulness of RIPK2 inhibitor
1 to alleviate the clinical symptoms associated with these
diseases.
Comparison with Recently Identified RIPK2 Inhibi-
tors. Recently, four inhibitors to RIPK2 were identified as
OD36/OD38 (Tigno-Aranjuez et al., 2014) WEHI-435
(Nachbur et al., 2015), GSK-583 (Haile et al., 2016), and the
one from Novartis (He et al., 2017). OD36 and OD38 were
obtained through a small molecule macrocylization process
from Oncodesign (Dijon Cedex, France) with IC50 values
of , 100 nM and the ability to interfere with MDP dependent
RIPK2 activity. WEHI-435 was obtained by analysis of the
RIPK2/ponatinib structure and the necrostatin-1/murine
RIPK1 structure to obtain a structural face for the murine
RIPK2 kinase domain (18–249) (Nachbur et al., 2015). Using
this structural face, the computational biology used to obtain
small molecules to associate with the RIPK2 ATP-binding
pocket, GSK-583, was obtained using structural comparisons
of RIPK2 with ponatinib. Last, the Novartis RIPK2 inhibitor
was obtained in a similar manner to GSK583 and was based
on a proprietary chemical library screen. Several hits were
obtained, and after structural optimization, a RIPK2 inhibitor
was obtained to inhibit RIPK2 kinase activity at 3 nM (He
et al., 2017).
In this study, we used similarity-based virtual screening
and molecular docking analysis to identify a RIPK2 inhibitor
that can empirically inhibit the autophosphorylation of
RIPK2, inhibit NFkB, and alleviate lung and intestinal
inflammation efficacious at 1–2 mg/g body weight. RIPK2
inhibitors did not inhibit RIPK1 activity involved in ferropto-
sis or cell death nor have an effect onmitochondrial biology. In
addition, RIPK2 inhibitor 1 appeared to also inhibit cell
proliferation as determined by MTT assay, which did not
appear to promote cell death. We find this curious and will be
further exploring how RIPK2 inhibitors 1 and 2 can promote
reduced proliferation and interfere with inflammation. In-
terestingly, RIPK2 has been demonstrated to be involved in
the active growth of CD90(1) intestinal stromal cells to
suggest an “inflammatory” cross-talk between intestinal
stromal cells and the epithelial cells (Owens et al., 2013),
and we can observe robust activation of RIPK2 in IBD colon
tissue sections immunostained with our proprietary pY474
RIPK2 antibody (Salla et al., unpublished observations).
Inflammation signals from stromal cells and the epithelial
cells will drive abnormal states to produce a cytokine storm
that fuels malignant growth. Inhibitors to RIPK2 may have
promising therapeutic potential to uniquely interfere with
NFkB-dependent biology and offer an alternative to existing
anti-inflammatory therapies.
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Supplementary Information, Experimental Procedures 
Pharmacokenetics. Intraperitoneal injection of 15 g/kg body weight of RIPK2 inhibitor 1 was carried out on wild type C56BL/6 mice. 
At the indicated times, cardiac puncture was performed and mouse serum obtained. Inhibitor 1 was measured in mouse serum injected 
using a high performance liquid chromatographic (HPLC) assay. To 0.1 mL of mouse serum in glass tubes was added 0.05 mL each of 
1 M NaOH and methanol. This was followed by addition of 3 mL of t-butyl methyl ether, vortex mixing for 30 sec at high speed, and 
centrifugation at high speed for 3 min. The supernatant was transferred to clean glass tubes and the solvent evaporated in vacuo. The 
residue was reconstituted in 0.15 mL of mobile phase and 0.05 mL injected into the HPLC. The mobile phase was a mixture of [25 mM 
KH2PO4: 3 mM sulfuric acid: 3.6 mM triethylamine]: acetonitrile in the proportion 64:36 v/v. The mobile phase was passed (0.9 mL/min 
at room temperature) in series through a C18 2 cm×4.0mm, 5m guard column (Supelco, PA, USA) then a Symmetry C18 analytical 
column, 3.5m, 150mm×4.6mm (Waters, MA, USA). Chromatographic data were collected and compiled by use of EZChrom software. 
Detection was by ultraviolet absorption using a Waters 486 detector, with the max being set to 261 nm. Standard curves of peak area or 
height from 25 to1000 ng/mL were highly linear (r2 > 0.99). 
 
Kinase Profiling. All assays are carried out in 97 well plate format as service at DiscoverX using their 97 target KinomeScan Profiling 
Service. For the 97 KinomeScan profiling assay, competition binding assays were carried as described previously (Karaman et al., 2008). 
Briefly, kinases were generated either as full length fusions to T7 phage6 or expressed in HEK-293 cells and subsequently tagged with 
DNA for PCR detection. For the binding assays, biotinylated affinity resins were coupled to streptavidin-coated magnetic beads, blocked 
with excess biotin and washed with blocking buffer (SeaBlock, Pierce) to remove unbound ligand and to reduce nonspecific binding. 
Binding reactions were initiated by combining kinase, liganded affinity beads and test compounds in binding buffer. Test compounds 
were prepared as 100 x stocks in DMSO and rapidly diluted into the aqueous environment. DMSO was added to control assays lacking 
a test compound. The assay plates containing kinase/ligand and small molecule inhibitor were incubated at 25 °C with shaking for 1 h, 
washed extensively to remove unbound protein and eluted. The kinase concentration in the eluates was measured by quantitative PCR. 
Each kinase was tested individually against each compound. Kds were determined using eleven serial threefold dilutions. 
 
Kinase Activity Assay for c-Abl. C-Abl kinase assay (Fig. 4D) was carried out by the MRC Protein Phosphorylation and Ubiquitylation 
Unit at http://www.ppu.mrc.ac.uk/. ABL (5-20mU diluted in 50 mM Tris pH 7.5, 0.1 mM EGTA, 1 mg/ml BSA) is assayed against 
substrate peptide (EAIYAAPFAKKK) in a final volume of 25.5 μl containing 50mM Tris pH 7.5, 0.1 mM EGTA, 1mM DTT, 300μM 
substrate peptide, 10 mM magnesium acetate and 0.005 mM [33P-γ-ATP] (50-1000 cpm/pmole) and incubated for 30 min at room 
temperature. Assays are stopped by addition of 5μl of 0.5 M (3%) orthophosphoric acid and then harvested onto P81 Unifilter plates 
with a wash buffer of 50 mM orthophosphoric acid. The dried Unifilter plates are then sealed on the addition of MicroScint O and are 
counted in Packard Topcount NXT scintillation counters.  
 
MTT Growth Assay. Cell proliferation assay was performed to evaluate cell viability after drug treatment. Cells were counted using 
hemocytometer and seeded in a 96-well plate at 1-2 X 104 cells/well and incubated for 24 hours. Different concentrations of RIPK2 
inhibitor was added to the cells and incubated for 48h. MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] was then 
added and incubated for 4h. Absorbance was measured at 560 nm using vICToR™ Multilabel Plate Reader from PerkinElmer. For 
L428, cells were stained with Trypan Blue to determine cell viability after 1 – 6 days incubation with the drugs. 
 
Immunoblot and Immunoprecipitation Analysis. Cells were collected and lysed using RIPA lysis buffer. Samples are denatured in 
SDS sample buffer and ran on 7.5% gel and blotted onto PVDF membrane. Blotted membranes are blocked with 10% milk for 30min 
and then incubated with primary antibodies overnight at 4oC. Membranes are then washed TBS-T (Tris-buffered saline containing 0.1% 
Tween 20) and incubated with appropriate secondary antibody (anti-rabbit or anti-mouse IgG) for one hour. 
 
Cell cycle analysis. MCF-7 or HCT116 cells were grown in 6-well plates and treated with the indicated compounds. Post-treatment, 
cells were trypsinised and resuspended in complete growth medium followed by centrifugation (230xg) and a 1XPBS wash. Cell pellets 
were gently resuspended in ice-cold 70% ethanol and a single cell suspension was made by gentle vortexing followed by overnight 
storage at -20°C. Next day, ethanol fixed cells were centrifuged (500xg) and washed twice with 1XPBS at 4°C. Propidium iodide 
staining of the cells was performed by incubating cell pellets in DNA staining solution (0.1% TritonX-100, 100 μg/ml DNAse free 
RNAseA, 20 µg/ml propidium iodide in 1XPBS) at 37°C for 30min followed by filtration through a nylon mesh (50 µM exclusion limit) 
to remove cell clumps. Flow cytometric analysis of was performed on a BD Accuri cell analyser). 
 
RIPK1 activity. HT-29, L929 and HaCaT cells were seeded in a 96-well plate and then treated with the indicated amounts of RIPK2 
inhibitors. After 24 hours, the media was removed and replaced with fresh media containing 20 μM z-VAD-fmk (Z), 100 nM Smac 
Mimetic-164 (S) and 10 ng/mL TNFα (T) in the presence or absence of 100 nM Ripk1 inhibitor or 1 uM necrosulfanamide (NSA) or 
the indicated amounts of RIPK2 inhibitors for 24 hours (HaCaT and HT-29) or 8 h (L929).  After the indicated time, the cells were 
double stained with hoechst and propidium iodide for 30 minutes at 37 degrees and then cell death was measured using the Celigo cell 
cytometer. 
 
Ferroptosis Analysis. A549 and U87 cells plated in 12 well dishes were pretreated with the inhibitors for one hour before the cells were 
treated with Erastin (a compound known to induce ferroptosis). After 48 hours, cells were harvested, re-suspended in PBS and stained 
with 0.04% trypan blue for 5-10 minutes at room temperature. Cell death was quantified by flow cytometry using the FACSCalibur flow 
cytometer and CellQuest software. Ferrostatin-1 (Fer-1) and Deferoxamine (DFO) were used as positive controls for the inhibition of 
ferroptosis. 
 
Assay of SIRT1 activity. The BIOMOL (Enzo Life Sciences) assay was performed as previously described (Hubbard et al., 2013). 2μg 
of recombinant SIRT1 was used for each reaction, and the β-NAD and FdL-p53 peptide concentrations used were 200 μM and 20 μM, 
respectively. 0.5 μL of vehicle or test compound was added to each 50 μL reaction. Fluorescence values corresponding to SIRT1 activity 
were calculated by subtracting parallel reactions in the absence of β-NAD from those in the presence of β-NAD (Fcorrected = F+NAD – F-
NAD).  Fold activation was calculated by dividing fluorescence values in the presence of drug by those in the presence of DMSO only. 
 
Supplementary Information, Tables and Figures 
Supplemental Table 1. Related to Table 1. Pharmacophore (Pharm) and similarity (Sim) compound ranking, PCFP similarity, chemical 
structure and SMILES of molecules retrieved from the pharmacophore and similarity-based virtual screenings. The compounds were 
also filtered for PAINS and aggregators (http://zinc15.docking.org/patterns/home/). 
 
Supplemental Table 2. Related to Figure 3. Kinome inhibition in the presence of 100 nM RIPK2 Inhibitor 1or 2.  Kinase activity assays 
of 97 kinases were carried using peptides or defined substrate as carried out by a “Kinome Scan” analysis by the DiscoverX 
(https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan/).  
 
Supplemental Figure 1 (A) The 1H-NMRchemical shift assignment of RIPK1 inhibitor 1: 10.32 (s, 1 H), 10.09 (s, 1 H), 8.13 (t, J = 2 
Hz, 1H), 8.02 (m, 3H), 7.88 (dt, J = 8 Hz, 2 Hz, 1H) 7.80 (dd, J = 8 Hz, 2Hz, 1H), 7.60-7.64 (m, 1H) 7.52-7.57 (m, 2H) 7.44-7.48 (m, 
2H) 7.42 (dt, J = 8 Hz, 2 Hz, 1H) 7.26 (d, J = 2 Hz, 1H) 6.94 (d, J = 2 Hz, 1H) 3.78 (s, 3H) 2.32 (s, 3H) ppm. (B) Analysis of through-
space connectivities suggested that RIPK2 inhibitor 1 has two major rotomeric forms in d6-DMSO. The second rotomer is slightly more 
favored, perhaps due to the formation of an intramolecular hydrogen bond. 
 
Supplemental Figure 2. (A) The 1H-NMR chemical shift assignment of RIPK1 inhibitor 2: 9.6 (s, 1 H), 8.31 (s, 1 H), 8.00 (dd, J = 9 
Hz, 2Hz, 1H), 7.86-7.93 (m, 3H), 7.45-7.52 (m, 2H), 7.37 (d, J = 9 Hz, 2H), 7.09 (d, J = 9 Hz, 2H), 6.9 (s, 1H), 4.32 (br, 1H), 4.10 (br, 
J = 12 Hz, 5 Hz, 2H) 3.8 (s, 3H), 3.02-3.14 (br, 2H), 2.85-2.92 (br, 2H), 2.78 (sep, J = 7Hz, 1H), 1.9-1.97 (br, 1H), 1.80-1.63 (br, 2H), 
1.44-1.54 (br, 2H), 1.40-1.29 (br, 2H), 1.20-1.26 (br, 1H), 1.15 (d, J = 7 Hz, 6H) ppm. Top, enlarged aromatic region; Bottom, full 1D. 
Note that 1H signals attached to C17-C25 are broadened by conformational exchange, indicating conformational transitions within the 
fused piperidine ring structure.  (B) Two-dimensional 1H-1H ROESY spectrum of [(2R,4S,5R)-5-[1-methyl-3-(naphthalen-2-yl)-1H-
pyrazol-5-yl]-1-azabicyclo[2.2.2]octan-2-yl]methyl N-[4-(propan-2-yl)phenyl]carbamate showing through-bond and through-space 
connections between hydrogen atoms. Boxes (blue) indicate cross peak signals due to 3-bond and 4-bond J-coupling. Signals due to 4-
bond J-coupling are less intense. Orange boxes denote through-space ROE connectivities. 
 
Supplemental Figure 3. Related to Figure 2. Mass spectrometry confirmation of mass for RIPK2 Inhibitor 2. (A) Direct-infusion 
measurements were carried out on an LTQ Orbitrap XL (Thermo Scientific) mass spectrometer using the Ion Max ESI source. Mass 
confirmation was obtained as indicated. (B) NFB gene reporter assay of inhibition of NFB activity with RIPK2 inhibitor 1 
(concentration as indicated and several stimuli presented). P values for TNF treatment was < 0.4; IL-1 was < 0.0007 and IFN- was 
< 0.07 (for inhibitor 1 treated vs non-treated). (C) RIPK2 inhibitor 1 effect on the activation of hypoxia response element (HRE) 
activation following 1% H2O2 addition overnight. P value for 1% H2O2 (treated with inhibitor 1 vs no drug) was < 0.02 (n = 3). 
 
Supplemental Figure 4. Related to Figure 5. Effect of RIPK2 inhibitors on NFB, cell growth and cell cycle control. (A) EMSA was 
carried out using the NFB binding site on the IL-6 promoter. HCT116 cells were pretreated with the indicated RIPK2 inhibitors for 2 
days, followed by stimulation with MDP and nuclear/cytoplasmic extraction. Four g of nuclear extract was incubated with the IL-6 
probe in an NFB DNA binding assay. (B) RIPK2 Inhibitor 1 can modulate the growth of several breast cancer cells.  MTT assay was 
carried out with the 100 nM of RIPK2 inhibitors in the indicated breast cancer cell lines with HCT1143 and MDA-MB31 as triple 
negative breast cancer cells and JMT-1 is a Her2 overexpressing cell line. For all experiments, n = 4 - 10. P value -/+ RIPK2 inhibitor 
1 for JMT-1 was 0.0001, for HCT1143 was 0.0007 and for MDA-MB231 was 0.05. (C) Growth inhibition MTT curves for HCT116 
(A) and BT-549 (B, breast cancer cells) were examined in the presence of RIPK2 inhibitor 1 at the concentrations indicated and 
approximate IC50 concentrations determined an indicated on top right portion of the graph. 
 
Supplemental Figure 5. RIPK2 inhibitor 1 does not affect the cell cycle fraction distribution at 100 nM. HCT-116 colon (A) or MCF-
7 breast (B) cancer cells were treated with Vehicle or the indicated inhibitors (5 M) for 36 hours. After an overnight ethanol fixation, 
cells were PI stained. 15000 cells were analyzed on BD Accuri flow cytometer. Different cell cycle phases were quantitated for 3 
independent experiments and plotted as percentage of mean ± SD (far right A and B). No major difference was observed between 
treatments. The data for 5 M of the drug is presented but similar results were observed at 100 nM RIPK2 inhibitor 1 drug treated cells. 
 
Supplemental Figure 6. Related to Figure 3, 4 and 5. RIPK2 inhibitors do not inhibit RIP1 or RIP3 Function. (A) Ferroptosis was 
measured in A549 lung cancer cells following treatment with Erastin. After 48 hours, cells were harvested, re-suspended in PBS and 
stained with 0.04% trypan blue for 5-10 minutes at room temperature. Cell death was quantified by flow cytometry using the 
FACSCalibur flow cytometer and CellQuest software. P value for Erastin vs. DMSO was < 0.0001; No significant differences were 
observed for Erastin vs. Erastin + inhibitor (1 or 2) (N=6). Similar results were obtained in the U87 cells.  (B) RIPK1 activity was 
measured in HT-29 cells by activation of cell death using 20 μM z-VAD-fmk (Z), 100 nM Smac Mimetic-164 (S) and 10 ng/mL 
TNFα (T) combination in the presence or absence of 100 nM Ripk1 inhibitor or 1 M necrosulfanamide (NSA) or the indicated amounts 
of RIPK2 inhibitors for 24 hours.  After the indicated time, the cells were double stained with hoechst and propidium iodide for 30 
minutes at 37 oC and then cell death was measured using the Celigo cell cytometer. The effect of the RIPK2 inhibitors on RIPK2-
directed cell death in L929 and HaCaT cells showed similar results.  P value for ZST vs DMSO was < 0.0001. No significant differences 
were observed for ZST vs. ZST + inhibitor (1 or 2). (C) Characterization of Sirtuin activity using the BIOMOL (Enzo Life Sciences) 
assay to monitor NAD activity. (D) Preliminary pharmacokenetics in mouse sera revealed a half-life of 1.89 hour and possible rapid 
metabolism of RIPK2 inhibitor 1 following 15 g/g intraperitoneal injection. Upper panel, Chromatograms from untreated mouse serum 
(bottom trace) and from a mouse serum sample containing 500 ng/mL of inhibitor 1 (upper trace). The inhibitor eluted at 3.7 min. Lower 
panel, mean ± SD serum concentration vs. time measures of Inhibitor 1 in sera from mice. 
 
Supplemental Figure 7. Related to Table 2 and Figure 6. Mice were exposed to 7 days of 3% DSS to induce inflammation injury and 
7 days with water to promote recovery. RIPK2 inhibitors were intraperitoneal (IP) injected on day 5, 7 and 9. Serum was harvested 11 
days after last IP injection and blood chemistry was carried out at the Prairie Diagnostics for numerous factors. The ones shown have 
some significant changes.  For alkaline phosphatase, Two-way Anova reveals P value < 0.0001 for all measured marker. 
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Salla et al, Supplemental Table 2
Kinase Species Entrez Gene Symbol RIPK2 Inhibitor 1 RIPK2 Inhibitor 2
% Activity Remaining % Activity Remaining
ABL1(E255K)‐phosphorylated ABL1 73 93
ABL1(T315I)‐phosphorylated ABL1 96 90
ABL1‐nonphosphorylated ABL1 95 89
ABL1‐phosphorylated ABL1 91 94
ACVR1B ACVR1B 97 99
ADCK3 CABC1 100 100
AKT1 AKT1 98 97
AKT2 AKT2 86 88
ALK ALK 90 100
AURKA AURKA 93 93
AURKB AURKB 78 97
AXL AXL 100 97
BMPR2 BMPR2 87 100
BRAF BRAF 100 96
BRAF(V600E) BRAF 100 99
BTK BTK 99 94
CDK11 CDK19 100 93
CDK2 CDK2 100 96
CDK3 CDK3 97 100
CDK7 CDK7 100 100
CDK9 CDK9 99 100
CHEK1 CHEK1 93 88
CSF1R CSF1R 100 89
CSNK1D CSNK1D 100 92
CSNK1G2 CSNK1G2 82 73
DCAMKL1 DCLK1 78 100
Salla et al, Supplemental Table 2 (Continued)
Kinase Species Entrez Gene Symbol RIPK2 Inhibitor 1 RIPK2 Inhibitor 2
% Activity Remaining % Activity Remaining
DYRK1B DYRK1B 95 94
EGFR EGFR 93 95
EGFR(L858R) EGFR 100 81
EPHA2 EPHA2 100 94
ERBB2 ERBB2 72 95
ERBB4 ERBB4 100 100
ERK1 MAPK3 97 91
FAK PTK2 100 94
FGFR2 FGFR2 93 72
FGFR3 FGFR3 100 85
FLT3 FLT3 89 100
GSK3B GSK3B 89 73
IGF1R IGF1R 97 89
IKK‐alpha CHUK 100 100
IKK‐beta IKBKB 100 100
INSR INSR 100 93
JAK2(JH1domain‐catalytic) JAK2 93 100
JAK3(JH1domain‐catalytic) JAK3 100 100
JNK1 MAPK8 89 73
JNK2 MAPK9 91 93
JNK3 MAPK10 83 81
KIT KIT 82 100
KIT(D816V) KIT 100 94
KIT(V559D,T670I) KIT 100 98
LKB1 STK11 89 95
MAP3K4 MAP3K4 93 94
MAPKAPK2 MAPKAPK2 99 87
MARK3 MARK3 100 100
Salla et al, Supplemental Table 2 (Continued)
Kinase Species Entrez Gene Symbol RIPK2 Inhibitor 1 RIPK2 Inhibitor 2
% Activity Remaining % Activity Remaining
MEK1 MAP2K1 89 98
MEK2 MAP2K2 83 89
MET MET 100 69
MKNK1 MKNK1 86 100
MKNK2 MKNK2 100 94
MLK1 MAP3K9 81 82
p38‐alpha MAPK14 100 100
p38‐beta MAPK11 100 97
PAK1 PAK1 98 95
PAK2 PAK2 94 100
PAK4 PAK4 99 100
PCTK1 CDK16 87 90
PDGFRA PDGFRA 86 88
PDGFRB PDGFRB 89 100
PDPK1 PDPK1 100 98
PIK3C2B PIK3C2B 95 100
PIK3CA PIK3CA 100 100
PIK3CG PIK3CG 100 100
PIM1 PIM1 100 94
PIM2 PIM2 98 99
PIM3 PIM3 94 100
PKAC‐alpha PRKACA 95 99
PLK1 PLK1 100 100
PLK3 PLK3 82 94
PLK4 PLK4 96 100
PRKCE PRKCE 100 100
RAF1 RAF1 95 100
Salla et al, Supplemental Table 2 (Continued)
Kinase Species Entrez Gene Symbol RIPK2 Inhibitor 1 RIPK2 Inhibitor 2
% Activity Remaining % Activity Remaining
RET RET 100 93
RIOK2 RIOK2 90 93
ROCK2 ROCK2 96 100
RSK2(Kin.Dom.1‐N‐terminal) RPS6KA3 99 100
SNARK NUAK2 100 62
SRC SRC 98 100
SRPK3 SRPK3 86 78
TGFBR1 TGFBR1 100 96
TIE2 TEK 97 96
TRKA NTRK1 86 90
TSSK1B TSSK1B 95 100
TYK2(JH1domain‐catalytic) TYK2 94 100
ULK2 ULK2 84 100
VEGFR2 KDR 96 83
YANK3 STK32C 94 84
ZAP70 ZAP70 100 85
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